PMID- 34007204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1178-7066 (Print)
IS  - 1178-7066 (Electronic)
IS  - 1178-7066 (Linking)
VI  - 14
DP  - 2021
TI  - Genetic Variants, Circulating Level of MCP1 with Risk of Chronic Obstructive 
      Pulmonary Disease: A Case-Control Study.
PG  - 561-567
LID - 10.2147/PGPM.S303799 [doi]
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) ranks one of the major 
      causes of mortality worldwide. Inflammation is greatly involved in the 
      pathogenesis of COPD. Monocyte chemoattractant protein-1 (MCP1) has been 
      implicated to play an important role in the inflammatory response of various 
      pathological processes. METHODS: In this study, we conducted a hospital-based 
      case-control study in a Chinese population, aiming to evaluate the potential 
      associations of genetic polymorphisms of the MCP1 gene (rs1024611, rs2857656, and 
      rs4586) and circulating level of MCP1 with COPD risk. RESULTS: We found that 
      rs1024611 (OR=1.37; 95% CI=1.11-1.69; P-value=0.004) and rs4586 (OR=1.33; 95% 
      CI=1.09-1.63; P-value=0.006) were significantly associated with increased COPD 
      risk. In the dominant model, both rs1024611 (OR=1.46; 95% CI=1.11-1.92; 
      P-value=0.006) and rs4586 (OR=1.56; 95% CI=1.18-2.07; P-value=0.002) were 
      significantly associated with increased COPD risk. Genotypes of rs1024611 and 
      rs4586 with minor alleles had a significantly higher circulating level of MCP1 
      (P<0.001). Meanwhile, a circulating level of MCP1 was significantly associated 
      with increased COPD risk (OR for per quartile increment=1.35, 95% CI=1.21-1.52, 
      P<0.001). CONCLUSION: Our study indicated that genetic polymorphisms of the MCP1 
      gene and circulating level of MCP1 contributed to the COPD risk in the Chinese 
      population. MCP1 contributed importantly to the pathophysiological process and 
      occurrence of COPD.
CI  - (c) 2021 Lin et al.
FAU - Lin, Chunyi
AU  - Lin C
AD  - Respiratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
FAU - Wang, Zhimin
AU  - Wang Z
AD  - Intensive Care Unit (ICU), The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
FAU - Shen, Lu
AU  - Shen L
AD  - Respiratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
FAU - Yi, Gao
AU  - Yi G
AD  - Respiratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
FAU - Li, Meichan
AU  - Li M
AD  - Respiratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
FAU - Li, Defu
AU  - Li D
AD  - Respiratory Medicine, The Fifth Affiliated Hospital of Guangzhou Medical 
      University, Guangzhou, 510700, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210511
PL  - New Zealand
TA  - Pharmgenomics Pers Med
JT  - Pharmacogenomics and personalized medicine
JID - 101514107
PMC - PMC8124012
OTO - NOTNLM
OT  - COPD
OT  - MCP1
OT  - case-control study
OT  - genetic
OT  - variation
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
PMCR- 2021/05/11
CRDT- 2021/05/19 06:45
PHST- 2021/01/26 00:00 [received]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2021/05/19 06:45 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
PHST- 2021/05/11 00:00 [pmc-release]
AID - 303799 [pii]
AID - 10.2147/PGPM.S303799 [doi]
PST - epublish
SO  - Pharmgenomics Pers Med. 2021 May 11;14:561-567. doi: 10.2147/PGPM.S303799. 
      eCollection 2021.